Skip to content
Science

Scientists warn that greener drug design is urgently needed to address environmental pollution

Monash University 2 mins read

The widespread contamination of ecosystems with pharmaceuticals poses a serious and growing threat to biodiversity, ecosystem services and public health. 

Urgent action is needed to design greener drugs that maintain efficacy while minimising environmental impact, according to an international study published in Nature Sustainability and involving Monash University researchers.

“In our increasingly medicated world, pharmaceuticals are essential to modern healthcare, having revolutionised disease prevention and treatment,” said co-lead author of the study Dr Michael Bertram, an Assistant Professor at the Swedish University of Agricultural Sciences, Umeå, Sweden, who also holds an adjunct position at the Monash University School of Biological Sciences.

“However, our growing dependence on pharmaceuticals comes at a major cost,” he said.

“Discharges during drug production, use and disposal have led to global contamination of ecosystems with mixtures of pharmaceuticals and their breakdown products. In fact, when patients take medicines, only a portion of those drugs are absorbed by the body, with the remainder being excreted and often released directly into the environment.”

Pharmaceutical contaminants have now been detected in environmental samples and the tissues of wildlife across all continents on Earth, including Antarctica. The pervasive spread of these contaminants, which are also found in groundwater used for drinking water, has led to the inclusion of several pharmaceuticals as priority substances in the new update to the European Water Framework Directive, a Europe-wide wastewater regulation.

“Evidence has been mounting for decades that trace concentrations of pharmaceutical pollutants and their mixtures can cause severe developmental, physiological, morphological, and behavioural changes in wildlife,” said co-author of the study Professor Bob Wong, from the Monash University School of Biological Sciences.

“For example, male fish exposed to estrogens found in the birth control pill exhibit feminisation and reproductive failure, leading to population collapse, while vultures exposed to anti-inflammatory drugs have undergone severe population crashes due to toxic effects,” he said.

“The impacts of pharmaceutical pollutants can have cascading effects on the ecology and evolution of wildlife populations and communities, potentially causing population declines and local extinctions.”

Pharmaceutical pollution poses threats to both wildlife and humans, such as the release of antibiotics into the environment promoting the spread of antibiotic resistance genes. 

This issue is exacerbated by other anthropogenic pressures, including climate change, habitat destruction and invasive species. Interactions between chemical pollutants and these other stressors can be additive or synergistic, further endangering biodiversity and ecosystem services.

“To address drug pollution, we urgently need to implement strategies to minimise environmental impacts across the entire pharmaceutical life cycle,” said study co-author Dr Lauren May, from the Monash Institute of Pharmaceutical Sciences.

“This includes promoting sustainable prescribing practices, increasing public awareness about the environmental impact of medicines, enhancing wastewater treatment processes, and actively pursuing eco-friendly drug design,” she said.

“Key to tackling this issue at its source is the design of greener pharmaceuticals that degrade more rapidly and completely in the environment,” says co-author Dr Manuela Jorg, also from the Monash Institute of Pharmaceutical Sciences.

The researchers say that greener pharmaceuticals should be designed for environmental degradation. The study argues that regulatory agencies should set standardised cut-off values for environmental persistence of pharmaceuticals, to limit the presence of harmful drugs in the environment. 

Media enquiries:

Silvia Dropulich
Marketing, Media and Communications Manager, Monash Science
T: +61 3 9902 4513 M: +61 435 138 743
Email: silvia.dropulich@monash.edu

Hande Cater
Media and Communications Manager, Monash University
M: +61 456 428 906
Email: hande.cater@monash.edu

General media enquiries:

Monash Media
T: +61 (0) 3 9903 4840
E: media@monash.edu
For more Monash media stories, visit our news and events site 

Media

More from this category

  • General News, Science
  • 19/12/2024
  • 10:00
Australian National Maritime Museum

DEEPSEA CHALLENGER returns home to Sydney in brand-new Maritime Museum exhibition

The Australian National Maritime Museum is thrilled to become the temporary home of the DEEPSEA CHALLENGER, the iconic submersible which took James Cameron to the deepest trenches of the ocean in 2012. It features within a brand-new exhibition, Ultimate Depth: A Journey to the Bottom of the Sea, opening on December 19, 2024. The DEEPSEA CHALLENGER, was designed, tested, and engineered in Sydney, was co-engineered by the renowned Ron Allum, a local Sydney cave diver, engineer, deep-sea explorer and former NSW Senior Australian of the Year. The Museum is honoured to have Ron Allum visit the exhibition for its launch…

  • Contains:
  • Engineering, Science
  • 19/12/2024
  • 09:00
UNSW Sydney

This purple diamond could one day amplify signals from deep space

They say that diamonds are a girl’s best friend – but that might also soon be true for astronomers and astrophysicists following new research…

  • Contains:
  • Medical Health Aged Care, Science
  • 18/12/2024
  • 08:58
Centenary Institute

Research grant to make gene therapy safer

A team led by Dr Chuck Bailey at the Centenary Institute has been awarded a National Health and Medical Research Council (NHMRC) Ideas Grant to develop safer and more effective gene therapies. The project will focus on improving the safety and efficacy of adeno-associated virus (AAV)-based gene therapies, a promising treatment approach for many genetic disorders. AAVs are naturally occurring viruses which can be harnessed to deliver good copies of genes into humans, thus enabling the treatment of diseases caused by faulty genes. While AAV therapies have transformed treatment options for certain conditions, significant challenges remain. One major hurdle is…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.